Open Menu
Topic: Analytical services

Insight & Resources

Webinar

Short-Term Solution or Long-Term Strategy? Planning for Outsourced Drug Development Shifts

Looking back over the past 2 years, the pandemic continues to test all standards and norms associated with drug development, including timelines, regulatory processes and inspections, manufacturing, and supply chain management. Through strategic partnerships and outsourcing strategies, pharmaceutical and biotech companies are enabling acceleration through collaboration.

As we begin to look forward to the future of drug development, watch our panel discussion examining new short- and long-term CDMO and supply chain strategies. Our panel, comprised of industry consultants and early development experts, discuss:

  • Approaches for building your early development outsourcing strategy
  • Considerations for vendor selection for pre-IND and phase-appropriate sourcing to mitigate supply chain disruption
  • Global vs. local sourcing strategies – from drug discovery to analytical and biopharmaceutical testing to manufacturing
  • Regulatory considerations for accelerating drug development

Speakers

Kyle Abuarjah, Founder & CEO, BioPulse Consulting

Kyle Abuarjah, Founder & CEO, BioPulse Consulting

Jeff Adams, General Manager and Site Lead, Cambrex Durham

Jeff Adams, General Manager and Site Lead, Cambrex Durham

Anas M. Fathallah, PhD, Co-founder and Scientific Lead, LAPIX Therapeutics, Inc

Anas M. Fathallah, PhD, Co-founder and Scientific Lead, LAPIX Therapeutics, Inc

Adam Lambert, PhD, Vice President, Product & Process Development, Pharmatech Associates

Adam Lambert, PhD, Vice President, Product & Process Development, Pharmatech Associates

Jennifer Therrien, Vice President, Marketing, Cambrex

Jennifer Therrien, Vice President, Marketing, Cambrex